Interpace Biosciences, Inc. (IDXG)
6.025
-0.36
(-5.71%)
USD |
OTCM |
Oct 02, 16:00
Interpace Biosciences Enterprise Value : 31.67M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 31.67M |
| October 01, 2026 | 33.69M |
| September 30, 2026 | 33.69M |
| September 29, 2026 | 33.85M |
| September 28, 2026 | 33.85M |
| September 25, 2026 | 33.80M |
| September 23, 2026 | 34.13M |
| September 22, 2026 | 34.13M |
| September 21, 2026 | 34.02M |
| September 18, 2026 | 34.02M |
| September 17, 2026 | 34.02M |
| September 16, 2026 | 34.02M |
| September 15, 2026 | 34.30M |
| September 14, 2026 | 33.19M |
| September 11, 2026 | 34.30M |
| September 10, 2026 | 34.69M |
| September 09, 2026 | 34.30M |
| September 08, 2026 | 36.58M |
| September 04, 2026 | 36.58M |
| September 03, 2026 | 34.35M |
| September 02, 2026 | 36.96M |
| September 01, 2026 | 37.07M |
| August 31, 2026 | 40.23M |
| August 28, 2026 | 40.49M |
| August 26, 2026 | 38.45M |
| Date | Value |
|---|---|
| August 25, 2026 | 37.62M |
| August 24, 2026 | 37.90M |
| August 21, 2026 | 40.47M |
| August 20, 2026 | 42.88M |
| August 19, 2026 | 41.78M |
| August 18, 2026 | 42.61M |
| August 17, 2026 | 45.38M |
| August 14, 2026 | 44.27M |
| August 13, 2026 | 44.55M |
| August 12, 2026 | 44.55M |
| August 11, 2026 | 44.52M |
| August 10, 2026 | 45.38M |
| August 07, 2026 | 42.88M |
| August 06, 2026 | 43.72M |
| August 05, 2026 | 39.77M |
| August 04, 2026 | 43.44M |
| August 03, 2026 | 42.33M |
| July 31, 2026 | 40.31M |
| July 30, 2026 | 38.18M |
| July 29, 2026 | 41.27M |
| July 28, 2026 | 41.29M |
| July 27, 2026 | 41.07M |
| July 24, 2026 | 38.73M |
| July 23, 2026 | 38.45M |
| July 22, 2026 | 40.11M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| PD-Rx Pharmaceuticals, Inc. | -- |
| Medical Marijuana, Inc. | 3.821M |
| Acro Biomedical Co. Ltd. | 1.943M |
| Stella Diagnostics, Inc. | 21.03M |
| ZeroStack Corp. | 11.60M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.266M |
| Revenue (Quarterly) | 9.131M |
| Total Expenses (Quarterly) | 8.865M |
| EPS Diluted (Quarterly) | 0.0285 |
| Gross Profit Margin (Quarterly) | 61.91% |
| Profit Margin (Quarterly) | 2.91% |
| Earnings Yield | 73.23% |
| Operating Earnings Yield | 12.48% |
| Normalized Earnings Yield | 72.98 |